Individuals who achieved a BMI of less than 25 kg/m2 in the SURMOUNT trials of tirzepatide also experienced significant ...
Analysis of the FOURIER trial shows that evolocumab provides greater MACE risk reduction in patients with higher BMI and stable ASCVD.
Children with higher polygenic scores showed accelerated BMI gain from age 2.5 years to adolescence in ALSPAC study. (HealthDay News) — Polygenic scores (PGSs) for body mass index (BMI) can improve ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback